|
Minkon Biotechnology Inc (MBI)
is a nutraceutical
and pharmaceutical company focusing on the development of innovative food
and health products for obesity prevention and treatment. It proposes to
deliver reliable and efficient weight management products to a market
suffering from a shortfall of options. The broad collaborations and
strategic partnerships with industry partners are being used for all aspects
of the product developments, including formulation, manufacturing,
preclinical/clinical studies.
Weight Loss
is a priority for
many of America’s 129.6 million overweight individuals. Obesity contributes
to other medical complications, including high blood pressure, hypertension,
high cholesterol, type II diabetes, coronary heart disease, congestive heart
failure, stroke, and certain types of cancer, to name a few. The emotional
strain experienced by America’s overweight citizens and the economic burden
on society as a whole is enormous. Meanwhile, there is a scarcity of safe
and effective options on the market. Minkon Biotechnology intends to solve
this problem with its proposed line of weight–loss products.
|
Our
Mission
|
To develop
and market safe and effective food and health products to improve the
lives of overweight and obese people. |
Recent News
March 5th, 2006
Minkon Biotechnology was chosen to attend the 8th Annual
Angel Venture Fair to be held on April 25th in Philadelphia.
July 28th, 2005
Maryland Technology Development Corporation (TEDCO)
Invests in Minkon Biotechnology.
more >>
About Obesity
Obesity on the Verge of Surpassing Smoking as #1 Cause of Preventable death.
Cost of Obesity to States Reached $75 Billion in 2003.
Obesity Passing Smoking as Top Avoidable Cause of Death
Obesity takes its toll on the
military.
Children are becoming increasingly
vulnerable to overweight and obesity around the world.
Check our library for more obesity information and
it's related diseases.
|
